Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Summary Zymeworks agreed to acquire Theravance Biopharma for $929 million, following the failure of ampreloxetine in neurogenic orthostatic hypotension. Consequently, Theravance entered a strategic review that identified its approved portfolio
Summary Tennessee enacted the FAIR Rx Act, banning pharmacy benefit manager-owned pharmacies from operating in the state. Express Scripts and the PCMA filed separate lawsuits in June 2026 to block
Summary Eli Lilly halted 340B drug discount pricing for a group of non-compliant US hospitals on June 19, 2026. The company says it needs claims data to prevent fraud and
Summary AbbVie announced Monday that it will acquire Apogee Therapeutics for $10.9 billion, or $135.11 per share — a 49% premium to Apogee’s closing price. The deal’s centerpiece is zumilokibart,
Summary A proposed CMS rule would close a formulation-switch loophole in Medicare’s drug price negotiation program. Merck’s Keytruda QLEX and Bristol Myers Squibb’s Opdivo Qvantig — subcutaneous versions of established
MARA Rating — Back-test series, June 2026 We built MARA to answer one question before the decision arrives: given this evidence profile, how have HTA bodies historically responded to assets
Deal Summary On June 9, 2026, GSK announced the acquisition of Nuvalent for $11 billion — paying $124 per share, a 40% premium over the prior trading price. The deal
Summary GSK announced the $11 billion acquisition of Nuvalent on June 9, 2026, gaining two experimental lung cancer drugs under FDA review. Zidesamtinib targets ROS1-positive NSCLC; neladalkib targets ALK-positive NSCLC.
Summary Incyte agreed to acquire Vega Therapeutics for $1.25 billion upfront on June 8, 2026, gaining VGA039, a subcutaneous monthly injection for von Willebrand disease (VWD), in Phase 3 testing.
On 9 June 2026, the European Commission published the first Joint Clinical Assessment (JCA) under the EU HTA Regulation. The drug assessed was tovorafenib (Ojemda), an oral RAF inhibitor for